NEW YORK, February 27 – Mike Treble, CEO of NimbleGen, believes that he can do for the microarray market what the PC did for computing, namely develop a technology cheap enough and easy enough to use to allow individuals to make their own high-quality microarrays.

"Our long term strategy over the next two to three years is to produce instruments that will allow core centers to produce their own DNA chips,” Treble told GenomeWeb. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.